Icahn Carl C Exits Position in Hologic (HOLX)

Hologic (HOLX) : Icahn Carl C has sold out all of its stake in Hologic during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 28,154,879 shares of Hologic which is valued at $1,089,030,720.

Other Hedge Funds, Including , D. E. Shaw boosted its stake in HOLX in the latest quarter, The investment management firm added 66,590 additional shares and now holds a total of 900,946 shares of Hologic which is valued at $34,848,591. Hologic makes up approx 0.07% of D. E. Shaw’s portfolio.Blackrock Fund Advisors boosted its stake in HOLX in the latest quarter, The investment management firm added 513,769 additional shares and now holds a total of 5,148,331 shares of Hologic which is valued at $199,137,443. Hologic makes up approx 0.04% of Blackrock Fund Advisors’s portfolio. Herndon Capital Management added HOLX to its portfolio by purchasing 22 company shares during the most recent quarter which is valued at $847.

Hologic opened for trading at $38.39 and hit $38.58 on the upside on Thursday, eventually ending the session at $38.46, with a gain of 0.10% or 0.04 points. The heightened volatility saw the trading volume jump to 16,99,124 shares. Company has a market cap of $10,670 M.

On the company’s financial health, Hologic reported $0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.48. The company had revenue of $717.40 million for the quarter, compared to analysts expectations of $703.38 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Many Wall Street Analysts have commented on Hologic. Company shares were Reiterated by RBC Capital Mkts on Aug 1, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 39 from a previous price target of $37 .

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.